U.S. markets open in 6 hours 22 minutes
  • S&P Futures

    4,206.75
    -16.25 (-0.38%)
     
  • Dow Futures

    33,864.00
    -153.00 (-0.45%)
     
  • Nasdaq Futures

    13,911.25
    -70.00 (-0.50%)
     
  • Russell 2000 Futures

    2,297.80
    -12.30 (-0.53%)
     
  • Crude Oil

    71.74
    -0.41 (-0.57%)
     
  • Gold

    1,816.00
    -45.40 (-2.44%)
     
  • Silver

    27.08
    -0.73 (-2.63%)
     
  • EUR/USD

    1.1979
    -0.0154 (-1.27%)
     
  • 10-Yr Bond

    1.5690
    0.0000 (0.00%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.3988
    -0.0095 (-0.67%)
     
  • USD/JPY

    110.6870
    +0.6530 (+0.59%)
     
  • BTC-USD

    39,149.04
    -1,275.61 (-3.16%)
     
  • CMC Crypto 200

    973.53
    -18.95 (-1.91%)
     
  • FTSE 100

    7,184.95
    0.00 (0.00%)
     
  • Nikkei 225

    29,018.33
    -272.68 (-0.93%)
     

Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020

·1 min read

GAITHERSBURG, Md., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases, today announced that four abstracts have been accepted for presentation, including a late-breaker, at the upcoming 8th Joint Congress of the American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The congress will be held virtually on September 11-13, 2020 with an Encore event featuring late-breaker and COVID-19 presentations on September 26, 2020.

Poster Presentations:
Title: AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder (P0189)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT

Title: Serum neurofilament light chain levels (sNfL) correlate with attack-related disability in neuromyelitis optica (P0155)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT

Title: Quiescent MRI activity in NMOSD: results from the N-MOmentum randomized placebo-
controlled trial (P0229)
Date: Friday, September 11, 2020
Time: 8:00 AM EDT

Late-Breaker Presentation:
Title: Pharmacodynamic modeling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders (LB1239)
Date: Saturday, September 26, 2020
Time: 8:00 AM EDT

About Viela Bio

Viela Bio, headquartered in Gaithersburg, Maryland, is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases. For more information, please visit www.vielabio.com.

Source: Viela Bio

Contacts:

Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com

Media:
Solebury Trout
Amy Bonanno
914-450-0349
abonanno@soleburytrout.com